2,168 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Angeles Wealth Management LLC

Angeles Wealth Management LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,168 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Stone Summit Wealth LLC lifted its position in Gilead Sciences by 6.3% during the 4th quarter. Stone Summit Wealth LLC now owns 30,503 shares of the biopharmaceutical company’s stock worth $2,818,000 after buying an additional 1,798 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Gilead Sciences during the 4th quarter worth about $33,000. Kestra Private Wealth Services LLC lifted its position in Gilead Sciences by 4.4% during the 4th quarter. Kestra Private Wealth Services LLC now owns 29,368 shares of the biopharmaceutical company’s stock worth $2,713,000 after buying an additional 1,247 shares in the last quarter. Empowered Funds LLC lifted its position in Gilead Sciences by 55.8% during the 4th quarter. Empowered Funds LLC now owns 219,579 shares of the biopharmaceutical company’s stock valued at $20,283,000 after purchasing an additional 78,657 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its position in Gilead Sciences by 6.8% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 19,933 shares of the biopharmaceutical company’s stock valued at $1,841,000 after purchasing an additional 1,273 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on GILD. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $84.00 target price on shares of Gilead Sciences in a research report on Monday, February 3rd. Wolfe Research began coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Finally, Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Price Performance

Shares of GILD opened at $95.48 on Tuesday. The stock has a market capitalization of $118.99 billion, a P/E ratio of 1,060.89, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The company has a 50 day moving average of $93.04 and a 200-day moving average of $86.86. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This represents a 43.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock valued at $53,611,715 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.